I reiterate a BUY rating with a $52/share price target, expecting double-digit returns as growth drivers materialize. Read more here.

II growth to AI-led efficiencies, explore how these listed players are balancing high transaction volumes with the challenge of sustainable profitability.

Curious how every single zodiac sign approaches wedding planning? An astrologer shares what the weddings of each sign might look like.

Discover how AI tools can enhance personal finance and investing strategies while navigating their limitations for optimal success.

Barclays demonstrated robust top-line growth, peer-leading margins, and global business diversification. Find out why BCS stock is a buy.

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...

Image courtesy by QUE.com Surge in Pre-Market Activity Sparks Market Speculation In a move that has captured the attention of analysts ...

Gold is now a dynamic instrument for liquidity rather than a static reserve in the fast-paced financial environment of February 2026. Even a tiny amount of gold may significantly increase capital at ...

Inflammatory bowel disease (IBD) patients may benefit from vitamin D, which helps rebalance immune responses to gut bacteria, and support gut health.

It was a cagey first 15 minutes, with the Bulls having the upper hand at scrumtime but neither side managing to stitch ...